THNLA-1 as radio/chemosensitiser of EMT-6 tumours in mice

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Papadopoulou, M V ^a   Ji, M ^a   Bloomer, W D ^a  

^a EVANSTON HOSPITAL   (United States)

Author keywords

Acridine; Hypoxia; Nitroimidazole; NLA 1; NLP 1; SR 2508; THNLA 1

Indexed keywords

CISPLATIN; NITROIMIDAZOLE; TACRINE; 9 (3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO) 1,2,3,4 TETRAHYDROACRIDINE; 9-(3-(2-NITRO-1-IMIDAZOLYL)PROPYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ETANIDAZOLE; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST TUMOR; CHEMOSENSITIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DNA BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; WHOLE BODY RADIATION; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG SYNERGISM; ETANIDAZOLE; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RADIATION-SENSITIZING AGENTS; TACRINE;

EID: 0029993225     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. BROWN JM, YU NY, BROWN DM AND LEE WW. (1981). SR-2508: a 2-nitro-imidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int. J. Radiat. Oncol. Biol. Phys., 7, 695-703.
2. COWAN DSM, PANICUCCI R, MCCLLELAND RA AND RAUTH AM. (1991). Targeting radio-sensitizers to DNA by attachment of an intercalating group: Nitroimidazole-linked phenanthridines. Radiat. Res., 127, 81-89.
3. DENNY WA, ROBERTS PB, ANDERSON RF, BROWN JM AND WILSON WR. (1992). NLA-1, A 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int. J. Radiat. Oncol. Biol. Phys., 22, 553-556.
4. GRAU C AND OVERGAARD J. (1988). Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol., 13, 301-309.
5. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol., 20, 45-50.
6. KENNEDY KA. (1987). Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des., 2, 181-194.
7. MOULDER JE AND ROCKWELL S. (1984). Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys., 10, 695-712.
8. MURRAY D AND MEYN RL. (1983). Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo. Br. J. Cancer, 47, 195-203.
9. PAPADOPOULOU MV, MAINWARING A AND BLOOMER WD. (1992a). Potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea's toxicity in vitro by two new bioreductive agents. Jpn. J. Cancer Res., 83, 907-913.
10. PAPADOPOULOU MV, EPPERLY MW, SHIELDS DS AND BLOOMER WD. (1992b). Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two new bioreductive compounds. Jpn. J. Cancer Res., 83, 410-414.
11. PAPADOPOULOU MV, MILLER A, SESKEY T, EPPERLY MW AND BLOOMER WD. (1993). Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents. Radiat. Oncol. Invest., 1, 206-217.
12. PAPADOPOULOU MV, ROSENZWEIG HS, DODDI M AND BLOOMER WD. (1994). 9-3-(2-Nitro-1-imidazolyl)propylamino-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol. Res., 6, 439-448.
13. PAPADOPOULOU MV, JI M, DODDI M AND BLOOMER WD. (1995). 9-3-(2- Nitro-1-imidazolyl)propylamino-1,2,3,4-tetrahydroacridine hydrochloride (THNLA-1) as chemosensitizer in vitro. In Proceedings of the 43rd Annual Meeting of the RRS and 15th Annual Meeting of the NAHS. San Jose, CA, April 1-6.
14. ROCKWELL SC, KALLMAN RF AND FAJARDO LF. (1972). Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl Cancer Inst., 49, 735-749.
15. SARTORELLI AC. (1988). Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res., 48, 775-778.
16. SIEMANN DW. (1984). Modification of chemotherapy by nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys., 10, 1585-1594.
17. TANNOCK I AND GUTTMAN P. (1981). Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br. J. Cancer, 42, 245-248.
18. WILSON WR AND DENNY WA. (1992). DNA-binding nitroheterocycles as hypoxia-selective cytotoxins. In Radiation Research : A 20th-Century Perspective, Dewey WC, Edington M, Fry RJM, Hall EJ and Whitmore GE. (eds) Vol. 2, pp. 796-801. Academic Press: New York.
19. WILSON WR, SIIM BG, DENNY WA, VANZIJL PB, TAYLOR ML, CHAMBERS DM AND ROBERTS PB. (1992). 5-Nitro-4-(N,N-dimethylamino-propylamino) quinoline (5-Nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: Comparison with nitracrine. Radiat. Res., 131, 257-265.